Expert Ratings For Amgen

In the latest quarter, 11 analysts provided ratings for Amgen AMGN, showcasing a mix of bullish and bearish perspectives.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

Analysts have recently evaluated Amgen and provided 12-month price targets. The average target is $314.55, accompanied by a high estimate of $360.00 and a low estimate of $235.00. This upward trend is evident, with the current average reflecting a 4.57% increase from the previous average price target of $300.80.

Exploring Analyst Ratings: An In-Depth Overview

The perception of Amgen by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Amgen. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Amgen compared to the broader market.
• Price Targets: Analysts predict movements in price targets, offering estimates for Amgen's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Amgen's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Amgen analyst ratings.

Discovering Amgen: A Closer Look

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen's Economic Impact: An Analysis

Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.

Positive Revenue Trend: Examining Amgen's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 21.98% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -1.52%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): Amgen's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -2.01%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): Amgen's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.12%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: Amgen's debt-to-equity ratio stands notably higher than the industry average, reaching 12.75. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.

Understanding the Relevance of Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.